Department of Abdominal Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
Department of Obstetric Gynaecology, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
Cancer Radiother. 2021 Apr;25(2):114-118. doi: 10.1016/j.canrad.2020.05.020. Epub 2021 Jan 22.
The breast sarcoma induced by radiation therapy is rare but increasing, given the increased long-term survival of patients receiving radiation therapy. Fibrosarcoma, histiocytofibroma and angiosarcoma are the most common breast sarcoma. Angiosarcoma is the most common after breast cancer treated by radiation therapy, often diagnosed too late, with a severe prognosis and a high rate of recurrence. However, because of the low incidence of angiosarcoma associated with radiation therapy (AAR), the benefit of radiation therapy in breast cancer treatment outweighs the risk to develop angiosarcoma. The aim of this study is to evaluate these rare cases of AAR diagnosed in eastern Belgium in comparison to the data from the literature.
Nine cases of AAR after radiation for breast ductal carcinoma were included in this retrospective study. AAR was diagnosed according to Cahan criteria between January 2007 and December 2016. Latency, incidence, management and prognosis are comparable to the literature.
RESULTS, CONCLUSION: The median latency was 10 (4-24) years, the incidence of AAR in the East Belgian area was 0.09% of the patients irradiated on the same period. Patients were treated by surgery with wide local excision with or without reconstructive surgery, without radiotherapy and chemotherapy treatment. Kaplan-Meier analysis showed median overall survival of 61.8 months, patient survival of 55.6% at one year and 29.6% at five years. With the constant progress of medicine and its technologies, it would be possible to limit the occurrence of AAR or to diagnose it at an earlier stage.
由于接受放射治疗的患者长期生存率提高,放射治疗引起的乳腺肉瘤越来越常见。纤维肉瘤、组织细胞纤维瘤和血管肉瘤是最常见的乳腺肉瘤。血管肉瘤是放射治疗后最常见的乳腺癌,通常诊断太晚,预后严重,复发率高。然而,由于与放射治疗相关的血管肉瘤(AAR)发病率低,放射治疗在乳腺癌治疗中的益处大于发生血管肉瘤的风险。本研究旨在评估在比利时东部诊断的这些罕见 AAR 病例,并与文献数据进行比较。
本回顾性研究纳入了 9 例因乳腺导管癌放射治疗后发生的 AAR 病例。根据 Cahan 标准,在 2007 年 1 月至 2016 年 12 月期间诊断为 AAR。潜伏期、发病率、治疗和预后与文献相似。
结果,结论:中位潜伏期为 10(4-24)年,同期接受放射治疗的患者中 AAR 的发病率为 0.09%。患者接受手术治疗,行广泛局部切除术,加或不加重建手术,不进行放射治疗和化疗。Kaplan-Meier 分析显示,总生存中位数为 61.8 个月,1 年时患者生存率为 55.6%,5 年时为 29.6%。随着医学及其技术的不断进步,有可能限制 AAR 的发生或更早诊断。